Canadian researchers scanning 24 people with long COVID found fewer dopamine nerve endings in the striatum, a shortfall tied to a quarter of symptom variance. The result gives drug trials a dopamine hypothesis to test, though the scan reads a protein marker that stands in for the neurons themselves.
Reality
- Evidence40
- Adoption
- Insufficient
- Hype gap+30
- Incentives55
- Confidence45
Mount Sinai's 30-person pilot found an at-home magnetic headset beat a sham on long COVID cognition, with gains holding a month after treatment ended. Only 10 people were in the sham arm, so the result argues for a larger trial before anyone calls the headset a treatment.
Reality
- Evidence35
- Adoption
- Insufficient
- Hype gap+35
- Incentives60
- Confidence40
Toronto scientists report reduced levels of a dopamine neuron marker throughout the striatum in people with long COVID, and the regional pattern tracked whether a patient's worst problem was motivation, movement or memory.
Reality
- Evidence40
- Adoption12
- Hype gap+35
- Incentives72
- Confidence55
Six years and thousands of studies have produced leads worth testing, but the researchers doing the work say the missing piece is a reliable disease marker, which is exactly what a trial needs to measure anything.
Reality
- Evidence58
- Adoption45
- Hype gap+8
- Incentives62
- Confidence60
An Institute for Systems Biology team names both the precursor cells and the signaling program behind them, which is what any drug program needs before it can start, though the published account reports no participant counts.
Reality
- Evidence58
- Adoption
- Insufficient
- Hype gap+18
- Incentives55
- Confidence55
A Nature cohort of 1,154 hospitalized patients ties lingering anellovirus activity to physical disability, which puts the sampling schedule, not the cytokine panel, at the center of trial design.
Reality
- Evidence64
- Adoption
- Insufficient
- Hype gap+18
- Incentives38
- Confidence58
Epstein-Barr infects about 95 percent of people and causes roughly 2 percent of cancers worldwide. It is also now tied to multiple sclerosis, with no approved vaccine and no antiviral to test the link.
Reality
- Evidence48
- Adoption8
- Hype gap+24
- Incentives40
- Confidence52
A Nature study of 1,154 hospitalized patients links Anelloviridae reactivation to lasting physical disability, which gives post-viral clinics something to measure instead of a syndrome of exclusion.
Reality
- Evidence58
- Adoption
- Insufficient
- Hype gap+28
- Incentives65
- Confidence52